Bramwell VH, Anderson D, Charette ML, et al. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrance Database Syst Rev, 3 : 2003
Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy : Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol, 34 : 786-793, 2016
Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le Cesne A, Sanfilippo R, Casieri P, Collini P, Dileo P, Spreafico C, Stacchiotti S, Tamborini E, Tercero JC, Jimeno J, D'Incalci M, Gronchi A, Fletcher JA, Pilotti S, Casali PG. Efficacy of trabectedin (ecteinascidin - 743) in advanced pretreated myxoid liposarcomas : a retrospective study. Lancet Oncol, 8 : 595-602, 2007
Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment if advanced or metastatic soft-tissue sarcoma : a randomized controlled phase 3 trial. Lancet Oncol, 15 : 415-423, 2014
Karavasilis V. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma : retrospective analysis and identification of prognostic factors in 488 patients. Cancer, 112 : 1585-. 2008